,source,page number,segment number,description,proposed_name,proposed_target,smiles,inchi,inchikey,validation
0,DH-MOTM-Poster-April-2023.pdf,0,0,"MK-0616
PCSK9
oral macrocyclic peptide inhibitor of PCSK9
Ph. III for hypercholesterolemia planned 2H 2023
from mRNA display + SBDD
J. Am. Coll. Cardiol., April 25, 2023
MERCK, RAHWAY, NJ
O
O",MK-0616,PCSK9,O.[H]C1[CH]OCC(=O)NCC2=CC=CCC3C(=C2)C[CH]32NC(=O)C(CNC(=O)CCCCC[N+](C)(C)C)NC(=O)C(C)NC(=O)CCC(=O)N(CCCCN[CH]C)(CCCCCCN3C=C(C[CH]NC2=O)C2=C3C=CC(F)=C2)CC2=CC=C(C=C2)CCNCC(C)NCC(CC2=CC=C(OC)C=C2)NCC(C(C)O)NC1=O,,,False
1,DH-MOTM-Poster-April-2023.pdf,0,1,"oral KRASG12C(ON) tri-complex inhibitor
Ph. I/Ib for adv. solid tumors
from FBDD + SBDD
AACR, April 2023
REVOLUTION MEDICINES, REDWOOD CITY, CA
RMC-6291
KRASG12C
O",oral KRASG12C(ON) tri-complex inhibitor,Ph. I/Ib for adv. solid tumors,CCn1c(-c2cccnc2[C@H](C)OC)c2c3cc(ccc31)N1CCO[C@@H](C[C@H](NC(=O)[C@H](C(C)C)N(C)C(=O)C3(F)CCN(C(=O)C#CC(C)(C)N(C)C)CC3)C(=O)N3CCC[C@H](N3)C(=O)OCC(C)(C)C2)C1,"InChI=1S/C55H78FN9O8/c1-13-64-44-19-18-37-30-40(44)41(48(64)39-16-14-24-57-46(39)36(4)71-12)32-53(5,6)34-73-51(69)42-17-15-25-65(59-42)50(68)43(31-38-33-63(37)28-29-72-38)58-49(67)47(35(2)3)61(11)52(70)55(56)22-26-62(27-23-55)45(66)20-21-54(7,8)60(9)10/h14,16,18-19,24,30,35-36,38,42-43,47,59H,13,15,17,22-23,25-29,31-34H2,1-12H3,(H,58,67)/t36-,38-,42-,43-,47-/m0/s1",HJNFYLSFWYRSHS-CMZSUCOPSA-N,True
2,DH-MOTM-Poster-April-2023.pdf,0,2,"camlipixant  
P2X3
oral BID P2X3 receptor antagonist
Ph. III for first-line treatment of refractory 
chronic cough
non-competitive homotrimeric receptor antagonist;
discovery not disclosed
GSK acquisition announcement, April 18, 2023
O
HN",camlipixant  ,P2X3,CNC(=O)c1cc(F)c(-c2nc3cc(C)ccn3c2C[C@H]2CN(C(=O)OC)CCO2)c(F)c1,"InChI=1S/C23H24F2N4O4/c1-13-4-5-29-18(11-15-12-28(6-7-33-15)23(31)32-3)21(27-19(29)8-13)20-16(24)9-14(10-17(20)25)22(30)26-2/h4-5,8-10,15H,6-7,11-12H2,1-3H3,(H,26,30)/t15-/m0/s1",SEHLMRJSQFAPCJ-HNNXBMFYSA-N,True
3,DH-MOTM-Poster-April-2023.pdf,0,3,"BAY-747
sGC
oral QD sGC stimulator
Ph. I in healthy volunteers completed
from HTS + optimization
J. Med. Chem., April 11, 2023
BAYER, WUPPERTAL, DE
NH2",BAY-747,sGC,CC[C@](C)(N)CNC(=O)c1c(C)nc2c(OCc3c(F)cccc3F)cc(C)cn12,"InChI=1S/C22H26F2N4O2/c1-5-22(4,25)12-26-21(29)19-14(3)27-20-18(9-13(2)10-28(19)20)30-11-15-16(23)7-6-8-17(15)24/h6-10H,5,11-12,25H2,1-4H3,(H,26,29)/t22-/m0/s1",MITNUFZPBQIMAT-QFIPXVFZSA-N,True
4,DH-MOTM-Poster-April-2023.pdf,0,4,"gepotidacin 
bacterial topoisomerase
oral BID antibacterial Type II topoisomerase inhibito
Ph. III for uncomplicated UTIs
from unbiased antibacterial screen + opt.
ECCMID, April 2023
GLAXO (GSK), STEVENAGE, UK
N
O",gepotidacin ,bacterial topoisomerase,O=c1ccc2ncc(=O)n3c2n1C[C@H]3CN1CCC(NCc2cc3c(cn2)OCCC3)CC1,"InChI=1S/C24H28N6O3/c31-22-4-3-20-24-29(22)15-19(30(24)23(32)13-27-20)14-28-7-5-17(6-8-28)25-11-18-10-16-2-1-9-33-21(16)12-26-18/h3-4,10,12-13,17,19,25H,1-2,5-9,11,14-15H2/t19-/m1/s1",PZFAZQUREQIODZ-LJQANCHMSA-N,True
5,DH-MOTM-Poster-April-2023.pdf,0,5,"CFT1946
BRAFV600X
oral mutant-selective BRAFV600X degrader
Ph. I for BRAF-driven cancers
from CRBN-based E3 recruiter + vemurafenib
AACR, April 2023
C4 THERAPEUTICS, WATERTOWN, MA
OH
O",CFT1946,BRAFV600X,CCN(C)S(=O)(=O)NC1=CC=C(C(=C1C#N)OC2=CC=C3C(=C2)C(=O)N(C=N3)[C@@H]4CC5(CCN(CC5)C(=O)CC6(CCN(CC6)C7=C(C=C8C(=C7)N(C)N=C8N9CCC(=O)NC9=O)F)O)OC4)F,"InChI=1S/C45H49F2N11O9S/c1-4-53(2)68(64,65)52-35-8-6-32(46)40(31(35)24-48)67-28-5-7-34-29(19-28)42(61)58(26-49-34)27-22-45(66-25-27)12-17-56(18-13-45)39(60)23-44(63)10-15-55(16-11-44)37-21-36-30(20-33(37)47)41(51-54(36)3)57-14-9-38(59)50-43(57)62/h5-8,19-21,26-27,52,63H,4,9-18,22-23,25H2,1-3H3,(H,50,59,62)/t27-/m1/s1",OCDRMYDQTIPVOI-HHHXNRCGSA-N,True
6,DH-MOTM-Poster-April-2023.pdf,0,6,"IOA-244
PI3Kd
oral QD non-competitive PI3Kd inhibitor
Ph. I in metastatic cancers
from focused kinase inhibitor screen (60K cmpds) 
+ opt.
Cancer Res. Commun., April 14, 2023
MERCK SERONO / IONCTURA, CH
O",IOA-244,PI3Kd,O=C(c1nn(-c2ccc(CN3CCOCC3)cc2)c2c1CS(=O)(=O)c1c(F)cccc1-2)N1CCOCC1,"InChI=1S/C26H27FN4O5S/c27-22-3-1-2-20-24-21(17-37(33,34)25(20)22)23(26(32)30-10-14-36-15-11-30)28-31(24)19-6-4-18(5-7-19)16-29-8-12-35-13-9-29/h1-7H,8-17H2",NFHSJYKXENYICE-UHFFFAOYSA-N,True
7,DH-MOTM-Poster-April-2023.pdf,0,7,"ARV-766
AR
oral AR-degrading PROTAC
Ph. II for adv. prostate cancer
from CRBN-based E3 recruiter + AR ligand
AACR, April 2023
ARVINAS, NEW HAVEN, CT
O
O",ARV-766,AR,COc1cc(OC2C(C)(C)C(NC(=O)c3ccc(N4CCC(CN5CCN(c6ccc(C(=O)N[C@H]7CCC(=O)NC7=O)c(F)c6)CC5)CC4)cc3)C2(C)C)ccc1C#N,"InChI=1S/C45H54FN7O6/c1-44(2)42(45(3,4)43(44)59-33-12-8-30(26-47)37(25-33)58-5)50-39(55)29-6-9-31(10-7-29)52-18-16-28(17-19-52)27-51-20-22-53(23-21-51)32-11-13-34(35(46)24-32)40(56)48-36-14-15-38(54)49-41(36)57/h6-13,24-25,28,36,42-43H,14-23,27H2,1-5H3,(H,48,56)(H,50,55)(H,49,54,57)/t36-,42?,43?/m0/s1",RDPPBRKNBBXPNZ-PJXMSJPKSA-N,True
8,DH-MOTM-Poster-April-2023.pdf,0,8,"difamilast
PDE4B
topical PDE4 inhibitor
marketed in Japan
PDE4B subtype-selective inhibitor; discovery 
not disclosed
JPET, April 11, 2023
OTSUKA, TOKYO, JP
O",difamilast,PDE4B,CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1,"InChI=1S/C23H24F2N2O5/c1-4-29-18-8-6-5-7-17(18)21(28)26-12-16-13-30-22(27-16)15-9-10-19(32-23(24)25)20(11-15)31-14(2)3/h5-11,13-14,23H,4,12H2,1-3H3,(H,26,28)",VFBILHPIHUPBPZ-UHFFFAOYSA-N,True
9,DH-MOTM-Poster-April-2023.pdf,0,9,"navoximod 
IDO
oral IDO1 inhibitor
Ph. I completed (50-800 mg) for cancer
from phenylimidazole + SBDD
JPET, April 14, 2023
NEWLINK / GENENTECH
N
OH
H
H",navoximod ,IDO,[H][C@]1([C@H](O)C[C@H]2c3c(F)cccc3-c3cncn32)CC[C@H](O)CC1,"InChI=1S/C18H21FN2O2/c19-14-3-1-2-13-16-9-20-10-21(16)15(18(13)14)8-17(23)11-4-6-12(22)7-5-11/h1-3,9-12,15,17,22-23H,4-8H2/t11-,12-,15-,17+/m0/s1",YGACXVRLDHEXKY-WXRXAMBDSA-N,True
10,DH-MOTM-Poster-May2023.pdf,0,0,"fenebrutinib
BTK
oral BTK inhibitor 
Ph. III for multiple sclerosis 
from ATP site-directed compound 
libraries + optimization 
Clinical data release, May 16, 2023
GENENTECH, SOUTH SAN FRANCISCO, CA",fenebrutinib,BTK,C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1,"InChI=1S/C37H44N8O4/c1-23-18-42(27-21-49-22-27)9-10-43(23)26-5-6-33(39-17-26)40-30-13-25(19-41(4)35(30)47)28-7-8-38-34(29(28)20-46)45-12-11-44-31(36(45)48)14-24-15-37(2,3)16-32(24)44/h5-8,13-14,17,19,23,27,46H,9-12,15-16,18,20-22H2,1-4H3,(H,39,40)/t23-/m0/s1",WNEODWDFDXWOLU-QHCPKHFHSA-N,True
11,DH-MOTM-Poster-May2023.pdf,0,1,"oral reversible pan-KRAS inhibitor 
oral activity in xenograft models (10-90 mpk BID) 
from prior covalent KRAS(G12C) inhibitor 
Nature, May 31, 2023 
BOEHRINGER INGELHEIM, VIENNA, AT
BI-2493
pan-KRAS
NH",oral reversible pan-KRAS inhibitor ,oral activity in xenograft models (10-90 mpk BID) ,C[C@H]1CNCCN1c1nccc(-c2noc3c2CCC[C@@]32CCCc3sc(N)c(C#N)c32)n1,"InChI=1S/C24H27N7OS/c1-14-13-27-10-11-31(14)23-28-9-6-17(29-23)20-15-4-2-7-24(21(15)32-30-20)8-3-5-18-19(24)16(12-25)22(26)33-18/h6,9,14,27H,2-5,7-8,10-11,13,26H2,1H3/t14-,24-/m0/s1",PVOYBVVIBNPTPJ-BSEYFRJRSA-N,False
12,DH-MOTM-Poster-May2023.pdf,0,2,"PF-07054894  
CCR6
oral, insurmountable, selective CCR6 antagonist 
Ph. I in HV completed, in Ph. I for ulcerative colitis 
from directed screening for novel negative 
allosteric modulators 
J. Pharm. Exp. Ther., May 4, 2023 
N
N",PF-07054894  ,CCR6,Cc1cn(C)nc1[C@H](Nc1c(Nc2ccnc(C(=O)N(C)C)c2O)c(=O)c1=O)C1(C)CCCC1,"InChI=1S/C24H30N6O4/c1-13-12-30(5)28-15(13)22(24(2)9-6-7-10-24)27-17-16(20(32)21(17)33)26-14-8-11-25-18(19(14)31)23(34)29(3)4/h8,11-12,22,27,31H,6-7,9-10H2,1-5H3,(H,25,26)/t22-/m0/s1",WZBSYWCLIMRAHO-QFIPXVFZSA-N,True
13,DH-MOTM-Poster-May2023.pdf,0,3,"ziritaxestat
ATX
oral ATX inhibitor 
negative outcomes in Ph. III in IPF (200-600 mg QD) 
from HTS and optimization 
JAMA, May 9, 2023 
GALAPAGOS SASU, ROMAINVILLE, FR
N",ziritaxestat,ATX,CCc1nc2c(C)cc(N3CCN(CC(=O)N4CC(O)C4)CC3)cn2c1N(C)c1nc(-c2ccc(F)cc2)c(C#N)s1,"InChI=1S/C30H33FN8O2S/c1-4-24-29(35(3)30-34-27(25(14-32)42-30)20-5-7-21(31)8-6-20)39-15-22(13-19(2)28(39)33-24)37-11-9-36(10-12-37)18-26(41)38-16-23(40)17-38/h5-8,13,15,23,40H,4,9-12,16-18H2,1-3H3",REQQVBGILUTQNN-UHFFFAOYSA-N,True
14,DH-MOTM-Poster-May2023.pdf,0,4,"OBI-3424 
AKR1C3-activated prodrug
IV AKR1C3-activated cytotoxin prodrug 
Ph. I/II in advanced solid tumors 
prodrug of DNA cross-linking agent 
Br. J. Cancer, May 12, 2023 
OBI PHARMA, TW; THRESHOLD PHARMA, CA
-
O
N",OBI-3424 ,AKR1C3-activated prodrug,C[C@@H](OP(=O)(N1CC1)N1CC1)c1ccc([N+](=O)[O-])c(Oc2cccc(C(=O)N(C)C)c2)c1,"InChI=1S/C21H25N4O6P/c1-15(31-32(29,23-9-10-23)24-11-12-24)16-7-8-19(25(27)28)20(14-16)30-18-6-4-5-17(13-18)21(26)22(2)3/h4-8,13-15H,9-12H2,1-3H3/t15-/m1/s1",NWGZZGNICQFUHV-OAHLLOKOSA-N,True
15,DH-MOTM-Poster-May2023.pdf,0,5,"TAK-994
OX2R
oral, brain-penetrant OX2R agonist 
Ph. II for narcolepsy; discontinued for safety signal 
from prior OX2R agonists derived from HTS 
J. Pharm. Exp. Ther., May 17, 2023 
TAKEDA, FUJISAWA, JP
F",TAK-994,OX2R,[H][C@]1(NS(C)(=O)=O)CCN(C(=O)C(C)(C)O)[C@@]1([H])Cc1cccc(-c2cc(F)cc(F)c2)c1F,"InChI=1S/C22H25F3N2O4S/c1-22(2,29)21(28)27-8-7-18(26-32(3,30)31)19(27)11-13-5-4-6-17(20(13)25)14-9-15(23)12-16(24)10-14/h4-6,9-10,12,18-19,26,29H,7-8,11H2,1-3H3/t18-,19-/m0/s1",VOSAWOSMGPKQEQ-OALUTQOASA-N,True
16,DH-MOTM-Poster-May2023.pdf,0,6,"ritlecitinib
JAK3/TEC
oral, dual JAK3/TEC kinase inhibitor 
Ph. III for alopecia areata 
structure-based design from tofacitinib 
The Lancet, May 6, 2023 
H
N",ritlecitinib,JAK3/TEC,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C,"InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1",CBRJPFGIXUFMTM-WDEREUQCSA-N,True
17,DH-MOTM-Poster-May2023.pdf,0,7,"LY03005
triple reuptake inhibitor
oral serotonin-norepinephrine-dopamine 
reuptake inhibitor 
approved in China for major depressive disorder 
from serotinin-norepinephrine reuptake 
inhibitor, desvenlafaxine 
Transl. Psychiatry, May 10, 2023 ",LY03005,triple reuptake inhibitor,Cc1ccc(C(=O)Oc2ccc(C(CN(C)C)C3(O)CCCCC3)cc2)cc1,"InChI=1S/C24H31NO3/c1-18-7-9-20(10-8-18)23(26)28-21-13-11-19(12-14-21)22(17-25(2)3)24(27)15-5-4-6-16-24/h7-14,22,27H,4-6,15-17H2,1-3H3",QKYBZJLEMOZFFU-UHFFFAOYSA-N,True
18,DH-MOTM-Poster-May2023.pdf,0,8,"TP0472993
20-HETE
oral 20-hydroxyeicosatetraenoic acid 
synthesis inhibitor 
preclinical efficacy in mouse kidney fibrosis model 
from in-house screen and optimization 
J. Pharm. Exp. Ther., May 4, 2023 
TAISHO PHARMACEUTICAL CO., JP
N
N",TP0472993,20-HETE,CC(=O)N1CCC(COc2ccc(-c3ccn[nH]3)nc2)CC1,"InChI=1S/C16H20N4O2/c1-12(21)20-8-5-13(6-9-20)11-22-14-2-3-15(17-10-14)16-4-7-18-19-16/h2-4,7,10,13H,5-6,8-9,11H2,1H3,(H,18,19)",GNQGSUOEYQIORN-UHFFFAOYSA-N,True
19,DH-MOTM-Poster-May2023.pdf,0,9,"VK2809 
THR-beta
oral THR agonist prodrug 
positive Ph. II data in NASH 
thyroid hormone mimetic prodrug 
Clinical data release, May 16, 2023 
METABASIS, CA / VIKING THERAPEUTICS, CA
OH",VK2809 ,THR-beta,CC(C)C1=CC(=CC=C1O)CC2=C(C)C=C(C=C2C)OC[P@@]3(=O)OCC[C@@H](C4=CC=CC(=C4)Cl)O3,"InChI=1S/C28H32ClO5P/c1-18(2)25-14-21(8-9-27(25)30)15-26-19(3)12-24(13-20(26)4)32-17-35(31)33-11-10-28(34-35)22-6-5-7-23(29)16-22/h5-9,12-14,16,18,28,30H,10-11,15,17H2,1-4H3/t28-,35+/m0/s1",LGGPZDRLTDGYSQ-JADSYQMUSA-N,True
